These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 33477163)

  • 1. Incremental Value of an Insertable Cardiac Monitor in Patients with Hypertrophic Cardiomyopathy with Low or Intermediate Risk for Sudden Cardiac Death.
    Sakhi R; Huurman R; Theuns DAMJ; Schinkel AFL; Assaf A; Szili-Torok T; Roos-Hesselink JW; Michels M; Yap SC
    Cardiology; 2021; 146(2):207-212. PubMed ID: 33477163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced American College of Cardiology/American Heart Association Strategy for Prevention of Sudden Cardiac Death in High-Risk Patients With Hypertrophic Cardiomyopathy.
    Maron MS; Rowin EJ; Wessler BS; Mooney PJ; Fatima A; Patel P; Koethe BC; Romashko M; Link MS; Maron BJ
    JAMA Cardiol; 2019 Jul; 4(7):644-657. PubMed ID: 31116360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.
    Maron BJ; Spirito P; Shen WK; Haas TS; Formisano F; Link MS; Epstein AE; Almquist AK; Daubert JP; Lawrenz T; Boriani G; Estes NA; Favale S; Piccininno M; Winters SL; Santini M; Betocchi S; Arribas F; Sherrid MV; Buja G; Semsarian C; Bruzzi P
    JAMA; 2007 Jul; 298(4):405-12. PubMed ID: 17652294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the new risk prediction model (HCM Risk-SCD) and classic risk factors for sudden death in patients with hypertrophic cardiomyopathy and defibrillator.
    Ruiz-Salas A; García-Pinilla JM; Cabrera-Bueno F; Fernández-Pastor J; Peña-Hernández J; Medina-Palomo C; Barrera-Cordero A; De Teresa E; Alzueta J
    Europace; 2016 May; 18(5):773-7. PubMed ID: 25855675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of arrhythmic events after alcohol septal ablation for hypertrophic cardiomyopathy using continuous implantable cardiac monitoring.
    Bleszynski PA; Goldenberg I; Fernandez G; Howell E; Younis A; Chen AY; McNitt S; Bruckel J; Ling F; Cove C; Aktas MK
    Heart Rhythm; 2021 Jan; 18(1):50-56. PubMed ID: 32853778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of patients with hypertrophic cardiomyopathy at risk of sudden cardiac death.
    Freitas P; Ferreira AM; Arteaga-Fernández E; de Oliveira Antunes M; Mesquita J; Abecasis J; Marques H; Saraiva C; Matos DN; Rodrigues R; Cardim N; Mady C; Rochitte CE
    J Cardiovasc Magn Reson; 2019 Aug; 21(1):50. PubMed ID: 31412875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypertrophic cardiomyopathy: the importance of arrhythmic events in patients at risk for sudden cardiac death.
    Medeiros Pde T; Martinelli Filho M; Arteaga E; Costa R; Siqueira S; Mady C; Piegas LS; Ramires JA
    Arq Bras Cardiol; 2006 Nov; 87(5):649-57. PubMed ID: 17221043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management and outcomes of hypertrophic cardiomyopathy in young adults.
    Baron É; Karam N; Donal E; Puscas T; Mirabel M; Bacher A; Wahbi K; Mazzella JM; Jeunemaitre X; Reant P; Hagège A;
    Arch Cardiovasc Dis; 2021; 114(6-7):465-473. PubMed ID: 33744178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness of an Implantable Loop Recorder to Detect Clinically Relevant Arrhythmias in Patients With Advanced Fabry Cardiomyopathy.
    Weidemann F; Maier SK; Störk S; Brunner T; Liu D; Hu K; Seydelmann N; Schneider A; Becher J; Canan-Kühl S; Blaschke D; Bijnens B; Ertl G; Wanner C; Nordbeck P
    Am J Cardiol; 2016 Jul; 118(2):264-74. PubMed ID: 27265676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of implantable cardioverter defibrillator therapy for primary and secondary prevention of sudden cardiac death in hypertrophic cardiomyopathy.
    Begley DA; Mohiddin SA; Tripodi D; Winkler JB; Fananapazir L
    Pacing Clin Electrophysiol; 2003 Sep; 26(9):1887-96. PubMed ID: 12930505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy.
    Maron BJ; Spirito P; Ackerman MJ; Casey SA; Semsarian C; Estes NA; Shannon KM; Ashley EA; Day SM; Pacileo G; Formisano F; Devoto E; Anastasakis A; Bos JM; Woo A; Autore C; Pass RH; Boriani G; Garberich RF; Almquist AK; Russell MW; Boni L; Berger S; Maron MS; Link MS
    J Am Coll Cardiol; 2013 Apr; 61(14):1527-35. PubMed ID: 23500286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy: efficacy and complications of the therapy in long-term follow-up.
    Syska P; Przybylski A; Chojnowska L; Lewandowski M; Sterliński M; Maciag A; Gepner K; Pytkowski M; Kowalik I; Maczyńska-Mazuruk R; Ruzyłło W; Szwed H
    J Cardiovasc Electrophysiol; 2010 Aug; 21(8):883-9. PubMed ID: 20132378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy.
    Maron BJ; Shen WK; Link MS; Epstein AE; Almquist AK; Daubert JP; Bardy GH; Favale S; Rea RF; Boriani G; Estes NA; Spirito P
    N Engl J Med; 2000 Feb; 342(6):365-73. PubMed ID: 10666426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implantable cardioverter defibrillators for primary prevention of sudden death in hypertrophic cardiomyopathy.
    Konstantinou DM; Efthimiadis GK; Vassilikos V; Paraskevaidis S; Pagourelias E; Maron BJ; Karvounis H
    J Cardiovasc Med (Hagerstown); 2016 Jun; 17(6):433-9. PubMed ID: 26885981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. QRS Fragmentation and QTc Duration Relate to Malignant Ventricular Tachyarrhythmias and Sudden Cardiac Death in Patients with Hypertrophic Cardiomyopathy.
    Debonnaire P; Katsanos S; Joyce E; VAN DEN Brink OV; Atsma DE; Schalij MJ; Bax JJ; Delgado V; Marsan NA
    J Cardiovasc Electrophysiol; 2015 May; 26(5):547-55. PubMed ID: 25648421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. QT prolongation and sudden cardiac death risk in hypertrophic cardiomyopathy.
    Patel SI; Ackerman MJ; Shamoun FE; Geske JB; Ommen SR; Love WT; Cha SS; Bos JM; Lester SJ
    Acta Cardiol; 2019 Feb; 74(1):53-58. PubMed ID: 29513133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypertrophic Cardiomyopathy-Related Sudden Cardiac Death in Young People in Ontario.
    Weissler-Snir A; Allan K; Cunningham K; Connelly KA; Lee DS; Spears DA; Rakowski H; Dorian P
    Circulation; 2019 Nov; 140(21):1706-1716. PubMed ID: 31630535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Appropriate Implantable Defibrillator Therapy in Adults With Hypertrophic Cardiomyopathy.
    Thavikulwat AC; Tomson TT; Knight BP; Bonow RO; Choudhury L
    J Cardiovasc Electrophysiol; 2016 Aug; 27(8):953-60. PubMed ID: 27138377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of the relationship between the ambulatory electrocardiography-based micro T-wave alternans and the predicted risk score of sudden cardiac death at 5 years in patients with hypertrophic cardiomyopathy.
    Özyılmaz S; Püşüroğlu H
    Anatol J Cardiol; 2018 Sep; 20(3):165-173. PubMed ID: 30152798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EvaLuation Using Cardiac Insertable Devices And TelephonE in Hypertrophic Cardiomyopathy (ELUCIDATE HCM)-rationale and design: a prospective observational study on incidence of arrhythmias in Sweden.
    Magnusson P; Mörner S
    BMJ Open; 2017 Dec; 7(12):e019541. PubMed ID: 29237655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.